Evidence map›Paper›PMID 40528426›Full record

ReviewObesity (Silver Spring, Md.)2025

Improving the diagnosis of hyperphagia in melanocortin-4 receptor pathway diseases.

M Jennifer Abuzzahab, Beatrice Dubern, Anthony P Goldstone, Andrea M Haqq, Steven B Heymsfield, Jennifer L Miller, Jesse Richards, Martin Wabitsch, Jack A Yanovski

Abstract readReview
In one paragraph

Review in Obesity (Silver Spring, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M Jennifer AbuzzahabDiabetes and Endocrine Center, Children's Minnesota, St Paul, Minnesota, USA.
Beatrice DubernSorbonne Université, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Anthony P GoldstonePsychoNeuroEndocrinology Research Group, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
Andrea M HaqqDivision of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
Steven B HeymsfieldPennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA.ORCID https://orcid.org/0000-0003-1127-9425
Jennifer L MillerDepartment of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA.
Jesse RichardsDepartment of Internal Medicine, University of Oklahoma at Tulsa, Tulsa, Oklahoma, USA.ORCID https://orcid.org/0009-0004-7985-8882
Martin WabitschDivision of Pediatric Endocrinology and Diabetes, Center for Rare Endocrine Diseases, Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany.
Jack A YanovskiSection on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-8542-1637

Funding

Rhythm Pharmaceuticals, Inc
6 · The paper itself

Abstract

Characteristics of hyperphagia include heightened and prolonged hunger, longer time to satiation, shorter duration of satiety, severe preoccupation with food (i.e., hyperphagic drive), abnormal food-seeking behaviors, and distress or functional impairment when food is unavailable. Patients with melanocortin-4 receptor (MC4R) pathway diseases including those caused by variants in one of multiple key genes of the pathway often present with hyperphagia that results in early-onset, severe obesity because this pathway plays a critical role in regulation of hunger/satiation and energy balance. Patients with syndromic obesity (e.g., Bardet-Biedl syndrome) may also have hyperphagia as a result of neurodevelopmental disruptions in the MC4R pathway. Genetic testing is suggested in patients with early-onset, severe obesity and clinical features of genetic obesity (e.g., hyperphagia, neurodevelopmental differences, dysmorphic features); however, only a small percentage of individuals who meet these criteria undergo testing, potentially owing to limited availability, overlapping symptoms with other obesity types, and infrequent use of genetic testing during diagnosis. Diagnosing hyperphagia may be challenging, as no guidelines have been established for individuals with MC4R pathway diseases. Identifying these individuals is crucial to addressing the challenges of hyperphagia and associated obesity, which often limit quality of life and place overwhelming burdens on patients and families.

Indexed as

HyperphagiaReceptor, Melanocortin, Type 4Bardet-Biedl SyndromeGenetic TestingHumansObesitySignal TransductionMC4R protein, humanReceptor, Melanocortin, Type 4

Identifiers

PMID40528426
PMCPMC12210103

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.